
German Chancellor Friedrich Merz and Brazilian President Luiz Inácio Lula da Silva met on the sidelines of G20 talks in South Africa on Saturday, after the German leader sparked outrage with comments on the Brazilian city hosting the COP30 climate talks.
Sources close to the chancellor described Saturday's meeting, which focused on the UN Climate Change Conference in Brazil, tropical rainforest protection and the war in Ukraine, as "very harmonious," though it was unclear whether Merz’s controversial comments were discussed.
Merz had travelled to the Amazon city of Belém for a summit two weeks ago ahead of the annual climate conference. On his return to Berlin, the chancellor said he had asked journalists who accompanied him whether any of them wanted to stay.
"No one raised their hand," Merz said. He argued that the reporters were "happy" to return to Germany, which he described as "one of the most beautiful countries in the world."
The statement triggered anger in Brazil, including from President Lula.
At the time, Lula said Merz should have gone to a bar in Belém, danced and tried out the local cuisine.
LATEST POSTS
- 1
Instructions to Really Oversee Unsold SUVs in the Auto Business - 2
Creative Do-It-Yourself Ventures for Each Expertise Level - 3
New York to require social media platforms to display mental health warnings - 4
Experience Sports in Dubai: A Daredevil's Aide - 5
UNICEF: More than 100 children killed in Gaza since ceasefire
The 10 Most Famous Works of art Ever
US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
Chicago reports first rabies-positive dog in 61 years. What we know.
A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
Woman gives birth on roadside after hospital allegedly sent her home: Family
Manual for Famous people Known for Their Altruistic Endeavors
The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
Holiday destinations for Creature Sweethearts
Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas













